Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.55 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.51 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28022779 | 0.84 | LMNA (0.54) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL641092 | 0.80 | PDE7A (0.63) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL1137534 | 0.79 | ALDH1A1 (0.47) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL30338244 | 0.79 | PDE7A (0.65) | PDE7APDE7BALDH1A1GSTP1GSTM2 | |
| SCHEMBL1713219 | 0.79 | PDE7A (0.65) | PDE7APDE7BALDH1A1GSTP1GSTM2 | |
| SCHEMBL10681839 | 0.77 | MEN1 (0.56) | ALDH1A1GSTP1GSTM2MAPTMEN1 | |
| SCHEMBL8757145 | 0.76 | MAPT (0.45) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL31354776 | 0.76 | CA12 (0.46) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL19048971 | 0.73 | PDE7A (0.71) | PDE7APDE7BPDE4BPDE4DALDH1A1 | |
| SCHEMBL9709555 | 0.73 | PDE7A (0.58) | PDE7APDE7BALDH1A1GSTP1GSTM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3066093-B9 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
| EP-3066093-B1 | GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-9718804-B2 | GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160272621-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-22 | — | — | US | disclosed |
| EP-3066093-A1 | GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069594-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069594-A1 | GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272621-A1 | GSK-3 INHIBITORS | GSK3B, GSK3A, GSKIP | PDE7A 2086/4885PDE7B 1940/4885PDE4B 2948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.